- Home
- IVP vs LIXT Comparison
IVP vs LIXT Comparison
Compare IVP & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- LIXT
- Stock Information
- Founded
- IVP 2020
- LIXT 2005
- Country
- IVP United States
- LIXT United States
- Employees
- IVP N/A
- LIXT N/A
- Industry
- IVP Diversified Commercial Services
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- LIXT Health Care
- Exchange
- IVP Nasdaq
- LIXT Nasdaq
- Market Cap
- IVP 3.3M
- LIXT 3.0M
- IPO Year
- IVP 2023
- LIXT N/A
- Fundamental
- Price
- IVP $1.66
- LIXT $0.74
- Analyst Decision
- IVP
- LIXT
- Analyst Count
- IVP 0
- LIXT 0
- Target Price
- IVP N/A
- LIXT N/A
- AVG Volume (30 Days)
- IVP 76.0K
- LIXT 82.2K
- Earning Date
- IVP 08-13-2025
- LIXT 08-07-2025
- Dividend Yield
- IVP N/A
- LIXT N/A
- EPS Growth
- IVP N/A
- LIXT N/A
- EPS
- IVP N/A
- LIXT N/A
- Revenue
- IVP $15,399,751.00
- LIXT N/A
- Revenue This Year
- IVP N/A
- LIXT N/A
- Revenue Next Year
- IVP N/A
- LIXT N/A
- P/E Ratio
- IVP N/A
- LIXT N/A
- Revenue Growth
- IVP N/A
- LIXT N/A
- 52 Week Low
- IVP $1.26
- LIXT $0.64
- 52 Week High
- IVP $401.50
- LIXT $3.00
- Technical
- Relative Strength Index (RSI)
- IVP 46.82
- LIXT 30.79
- Support Level
- IVP $1.51
- LIXT $0.64
- Resistance Level
- IVP $1.76
- LIXT $0.93
- Average True Range (ATR)
- IVP 0.13
- LIXT 0.13
- MACD
- IVP -0.02
- LIXT -0.05
- Stochastic Oscillator
- IVP 18.43
- LIXT 16.99
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.